Neurocrine Biosciences to acquire Soleno Therapeutics Neurocrine Biosciences announced a $2.9 billion acquisition of Soleno Therapeutics, a company developing a treatment for Prader Willi syndrome. The deal structure centers on Neurocrine paying $53 per share for Soleno. The acquisition matters…
Continue reading...
Continue reading...